olfactory receptor family 13 subfamily Z member 3 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR13Z3P profile across patient tissues and cancer cell-line models. OR13Z3P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR13Z3P is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, OR13Z3P RNA expression shows 4,673 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where OR13Z3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR13Z3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR13Z3P survival associations across molecular data types. OR13Z3P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR13Z3P RNA expression–survival associations across cancer types. High OR13Z3P expression shows unfavorable associations in STAD, KIRC, ACC, CESC, COAD and HNSC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for OR13Z3P RNA expression.
This table summarizes OR13Z3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR13Z3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR13Z3P shows higher tumor expression in LUAD. The LUAD box plot shows higher OR13Z3P RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .016).
This table shows molecular features associated with OR13Z3P in patient tissues and cancer cell lines. In patient samples, OR13Z3P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
